|
|
 |
|
Viewing report
|
|
|
|
Glycogen Synthase Kinase 3 (GSK-3) and Its Inhibitors: Drug Discovery and Development
John Wiley and Sons Ltd, Dec 2006, Pages: 346
The new potential of an 'old' enzyme
Glycogen Synthase Kinase 3 (GSK-3) was discovered about twenty-five years ago but had garnered little interest until recently. Now many researchers believe that there is much potential for this 'old' enzyme and are re-examining its biological characteristics. GSK-3 and its inhibitors could lead to effective treatments for neurogenerative disorders, type II diabetes, depression and bipolar disorder, and some forms of cancer. This book explores the nature of this promising enzyme, providing a thorough introduction and discussion, and mentions the birth of several chemical families of GSK-3 inhibitors with varying selectivity.
Specific topics relating to GSK-3 covered in this book include:
- Cellular functions
- Neuronal cell biology
- Crystal structures
- Kinase-kinase and site-site interactions in the phosphorylation of tau
- Therapeutic target in human pathology
- Role in stem cells
- Physiology studies
- Development and therapeutic potential of GSK-3 inhibitors
Gathering and systematically analyzing relevant and up-to-date information about GSK-3 and its known inhibitors, this book will aid researchers interested in drug design and development, especially those directly involved in the fascinating world of GSK-3.
Author Information
ANA MARTINEZ is the Research and Development Director for NeuroPharma. She has been and still is an active researcher in the design and synthesis of GSK-3 inhibitors.
ANA CASTRO is the Medicinal Chemistry Director of NeuroPharma. She was formerly a tenured scientist at the Medicinal Chemistry Institute.
MIGUEL MEDINA is the Drug Discovery Director at NeuroPharma. He was formerly an instructor at the Brigham and Womens Hospital and the Harvard Medical School.
Customers who bought this item also bought
Glycogen Synthase Kinase-3 (GSK-3) and Its Inhibitors: Drug Discovery and Development
Glycogen synthase kinase 3 inhibitors: Proof of concept and therapeutic opportunities for the treatment of diabetes, Alzheimer's disease, stroke and bipolar disorder
Competitor Analysis: Protein Kinase C (PKC) Inhibitors
The Drug Target Atlas of Protein Kinase Inhibitors in Oncology
Competitor Analysis: Aurora Kinase Inhibitors
Brief Report: Syk Kinase Inhibitors
Competitor Analysis: Bcr-Abl and Src Kinase Inhibitors
Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications
Competitor Analysis: Novel Mitotic Kinase Inhibitors
Aurora Kinase inhibitors - The dawn of a new approach to cancer
Triple Progress Analysis: Lymphoma Therapeutics, Protein Kinase Inhibitors & Therapeutic Antibodies
Analytical Tool - Protein Kinase Inhibitors in Oncology 2009
|
|
|
|
